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Introduction
Over the last few years, technological advances have
led to identify important biological and genetic
parameters related to the clinical course of B-cell
chronic lymphocytic leukaemia (B-CLL). The
immunoglobulin variable heavy chain (IgVH) gene
was determined as one of the most powerful prog-
nostic factors, where B-CLL cases with unmutated
IgVH genes are characterized by an unfavorable clin-
ical outcome, whereas the prognosis for patients with
germline status is unfavourable [1,2]. Recently two
other prognostic parameters were also identified in
patients with B-CLL: intracellular ZAP-70 expres-
sion [3,4] and cell-surface expression of CD38 on
leukemic cells [1,5]. In contrast to technically
demanding and expensive method of IgVH mutations
analysis, both markers can be conveniently measured
using the flow cytometry method. ZAP-70 (zeta-
associated protein) was shown to be the most promis-
ing surrogate marker for IgVH mutation status with a
high predictive value. CD38 expression was also ini-
tially reported by Damle et al. to be correlated with
IgVH mutations [1], however subsequent studies
showed only some degree of correlation [6,7]. Irre-
spective of the extent of concordance with rearrange-
ment of the IgVH genes, CD38 expression was
proved by many investigators to be a reliable predic-
tor of the outcome in B-CLL [8,9]. In the literature,
there are only few studies [10,11], including our pre-
liminary data [12] reporting clinical significance of
combined expression of ZAP-70 and CD38 in pre-
dicting the outcome of B-CLL patients. In order to
clarify further prognostic impact of combined analy-
sis of ZAP-70 and CD38 we examined the expression
of both factors in peripheral blood samples obtained
from 217 newly diagnosed, consecutive, unselected
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 46, No. 2, 2008
pp. 147-152
ZAP-70 and CD38 expression are independent prognostic
factors in patients with B-cell chronic lymphocytic
leukaemia and combined analysis improves their
predictive value
Iwona Hus1, Agnieszka Bojarska-Junak2, Anna Dmoszyñska1, Ewa W¹sik-Szczepanek1,
Ma³gorzata Sieklucka1, Wioletta Trzeœniewska1, Magdalena Glazer2, Jacek Roliñski2
1Department of Haematology and Bone Marrow Transplantation, Medical University of Lublin 
2Department of Clinical Immunology, Medical University of Lublin
Abstract: Recently identified biological risk factors in B-cell chronic lymphocytic leukemia (B-CLL) include ZAP-70 and
CD38 expression. The present study was conducted to clarify whether a combined analysis could improve predictive impact
of these two parameters. We examined the expression of ZAP-70 and CD38 by flow cytometry method in 217 newly diag-
nosed, consecutive, unselected and well characterized B-CLL patients in relation to laboratory parameters and clinical out-
come. We confirmed that both ZAP-70 as well as CD38 were independent of prognostic factors. There was a significant cor-
relation between the percentage of leukemic cells positive for ZAP-70 and the percentage of CD38+CD19+ cells (R=0.629;
p=0.000001). Combined analysis of ZAP-70 and CD38 showed concordant results in 158/217 patients (72.8%), while in 59
patients the results were discordant (27.2%). A mean treatment free survival (TFS) was the longest in ZAP-70-CD38-
patients (45.6 months, comparing to 13.6 months in ZAP-70+CD38+ group). Also a mean overall survival was the longest
in ZAP-70-CD38- patients (224.7 months compared to 77.9 months in ZAP-70+CD38+ patients).
Key words: B-cell chronic lymphocytic leukaemia - Prognostic factors - ZAP-70 - CD38
Correspondence: I. Hus, Haematooncology Department, 
Medical University of Lublin, Staszica Str. 11, 20-081 Lublin,
Poland; tel.: (+4881) 5345468, fax.: (+4881) 5345605, 
e-mail: iwohus@wp.pl
and well characterized B-CLL patients in relation to
laboratory parameters and clinical outcome. 
Materials and methods
Patients. Two hundred seventeen newly diagnosed and previously
untreated, consecutive, unselected B-CLL patients were enrolled
into this study from 1987 to 2006. Diagnosis of B-CLL was made
on the basis of a clinical examination as well as morphological and
immunological criteria described by NCI-WG (National Cancer
Institute-Working Group) [13]. There were 78 women and 139
men (M : F  ratio - 1:1.78 with a median age of 64 years (range 34
- 86) at the time of diagnosis. Patients were staged according to the
Rai classification. Fifty patients were diagnosed at stage 0 and fifty
five at stage 1, sixty at stage 2, and twenty-five and twenty seven
at stages 3 and 4, respectively. For statistical analyses modified Rai
stages were used. Fifty patients had low-modified Rai stage, 115
had intermediate stage and 52 had high stage. All peripheral blood
samples were collected in heparinized tubes and immediately
processed. Mononuclear cells were isolated by density gradient
centrifugation on Gradisol L (Aqua Medica, Poland). Interphase
cells were removed and washed twice in phosphate-buffered saline
(PBS) and then resuspended at 1×106 cells for future staining.
Cell-surface antigen expression. Peripheral blood mononuclear
cells were stained with the following antibody conjugates: negative
control IgG1 FITC/IgG2a PE/IgG2a TC, anti-CD45 FITC/ anti-
CD14 PE (Caltag Laboratories, USA), anti-CD19 PE, anti-CD19
FITC, anti-CD3 PE (BD PharMingen, USA), anti-CD19 TC (PE-
Cy5), anti-CD5 TC  (PE-Cy5), anti-CD3 FITC/ anti-CD19 PE,
anti-CD8 FITC/ anti-CD4 PE, anti-CD5FITC/anti-CD19PE (Calt-
ag Laboratories, USA. 5 μl of each MoAb was added to the appro-
priate tubes and incubated for 20 min at RT. Finally, the cells were
washed and analyzed by flow cytometry.
Flow cytometry analysis. Samples were analysed by flow cytom-
etry using a Becton Dickinson FACSCalibur instrument equipped
with a 488-nm argon laser. Five data parameters were assessed: lin-
ear forward and side scatter (FSC, SSC), FL-1(FITC), FL-2(PE)
and FL-3 (CyChrome). An acquisition gate was established on the
basis of FSC and SSC that included mononuclear cells and exclud-
ed dead cells and debris. For each analysis 10.000 events were
acquired and analysed using CellQuest software. Each sample was
run with an appropriate isotype control and this was used to define
the negatively stained cells.
ZAP-70 staining using ZenonTM Alexa Fluor 488 Mouse IgG2a
Labeling Kit. All samples were stained for ZAP-70 protein
expression. We used the method described earlier [14]. Anti-ZAP-
70 antibody, clone 2F3.2 (mouse monoclonal IgG2a), was pur-
chased from Biomol Research Laboratories. ZenonTM Alexa Fluor
488 Mouse IgG2a Labeling Kit was obtained from Molecular
Probes. CyChrome conjugated monoclonal antibody (MoAb) anti-
CD5, CyChrome conjugated MoAb anti-CD19 and PE conjugated
MoAb anti-CD19 were obtained from Caltag Laboratories. 
100 μl of peripheral blood mononuclear cells (1×106cells/mL)
were stained with MoAbs against the cell-surface markers CD19
PE and CD5 CyChrome. The cells were then fixed in a 1%
paraformaldehyde solution in PBS for 15 minutes at room temper-
ature (RT) and permeabilized with 70% ethanol for at least 1 hour
at -20°C. Thereafter, anti-ZAP-70 antibody labelled by the Zenon
mouse IgG labelling reagents was added to the sample tubes. The
samples were incubated for 30 minutes at RT, washed and imme-
diately analysed by flow cytometry.
Zenon Complex Formation. For ZAP-70 staining 1 μg cells of
anti-ZAP-70 antibody per 106 cells was evaluated. Anti-ZAP-70
antibody was prepared in 20 μl of PBS. Next, the Zenon mouse
IgG labelling reagent, which contained a fluorophore-labelled
Fab fragment, was added to the antibody solution (5 μl of the
Zenon labelling reagents were used for each 1 μg of IgG). The
mixture was incubated for 5 minutes at RT. Then 5 μl of the
Zenon blocking reagent was added to the reaction mixture. The
solution was incubated for additional 5 minutes and applied to the
sample.
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Table 1. Cox regression analysis of prognostic factors for B-CLL.
Table 2. Comparison of laboratory parameters in groups of patients with B-CLL according to ZAP-70 and CD38 expression. p1-between
ZAP-70-CD38- group and ZAP-70-CD38+group (not significant); p2-between ZAP-70-CD38- group and ZAP-70+CD38-group; p3-
between ZAP-70-CD38-group  ZAP-70+CD38+ group (only significant p values shown).
Statistical analysis. The statistical significance of the flow cyto-
metric results was analysed by means of the Mann-Whitney U test.
Spearman rank test was used to assess the correlation between the
variables. Analysis of the effect of potential prognostic factors was
undertaken using a Cox regression. Treatment free survival time
and overall survival time measured from diagnosis were estimated
according to the method of Kaplan-Meier and compared between
groups by means of log-rank test. Differences were considered as
statistically significant when the p-value was <0.05. We used Sta-
tistica 5.0 PL software for all statistical procedures. 
Results
Cox proportional hazards regression analysis
Using Cox proportional hazards regression analysis,
we compared ZAP-70 and CD38 expression with
other prognostic factors, namely age >60 years, clin-
ical stage, white blood cell, lymphocyte and platelet
count, hemoglobin level, serum concentration of
LDH and β2-microglobulin (β2M). Univariate analy-
sis of the overall survival identified 6 significant fac-
tors: Rai stage of the disease, platelet count, hemo-
globin level and LDH concentration, as well as ZAP-
70 and CD38 expression, which subsequently were
included in multivariate Cox regression analysis.
Only hemoglobin concentration, ZAP-70 and CD38
expression remained significant and were confirmed
to be independent prognostic factors (Table 1).
Correlation between ZAP-70 and CD38 
expression
Spearman rank-correlation test revealed significant
correlation between the percentage of leukemic cells
with ZAP-70 expression and the percentage of
CD38+CD19+ cells in the whole patients group
(r=0.629; p=0.000001) (Fig. 1).
To evaluate further correlation between ZAP-70
and CD38 expression the patients were divided into
four groups.  Entire correlation between the expres-
sion of studied parameters was noted in 158/217
patients (72.8%). Among them there were 105 ZAP-
70-/CD38- patients (48.4%) and 53 ZAP-70+CD38+
patients (24.4%). Among the remaining 59 patients,
25 were ZAP-70-CD38+ (11.5%) and 34 ZAP-
70+CD38- (15.7%). Table 2 presents the comparison
of clinical and laboratory parameters with four
groups of patients mentioned above. The most sig-
nificant differences were revealed among the
patients characterized by positive ZAP-70 and CD38
expression as well as lack of expression in the two
studied proteins. The differences referred to all eval-
uated laboratory parameters. The only significant
difference among the remaining groups concerned a
higher number of PLT count in the group of ZAP-70-
CD38- patients in comparison with ZAP-70+CD38-
ones (Table 2). 
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Fig. 1. Correlation between intracelullar expression of ZAP-70
and expression of CD38 on leukaemic cells (Spearman rank-cor-
relation  test).
Fig. 2. Kaplan-Meier's curves presenting TFS in groups of B-CLL
patients with phenotype: ZAP-70-CD38-; ZAP-70-CD38+; ZAP-
70+CD38-; ZAP-70+CD38+.
Fig. 3. Kaplan-Meier's curves presenting OS in groups of B-CLL
patients with phenotype: ZAP-70-CD38-, ZAP-70-CD38+, ZAP-
70+CD38- and ZAP-70+CD38+.
Treatment-free survival (TFS) and overall 
survival (OS) in relation to combined ZAP-70
and CD38 expression
In order to define the impact of simultaneous ZAP-70
and CD38 expression on  TFS, the analysis of  Kaplan-
Meier's curves was done in the following groups of
patients: ZAP-70+CD38+; ZAP-70-CD38-; ZAP-70-
CD38+ and ZAP-70+CD38-. It was found that TFS
curves for groups ZAP-70-CD38- and ZAP-
70+CD38+, as well as groups ZAP-70+CD38- and
ZAP-70+CD38+ showed essential differences
(p=0.0004, p=0.0499, log-rank test). A significant dif-
ference in TFS between groups ZAP-70+CD38- and
ZAP-70+CD38+ suggests that in the group of patients
with positive ZAP-70 expression, defining CD38
expression enables also to distinguish patients with
better and worse prognosis  (Fig. 2). With the data pre-
sented in Table 3 one may come to conclusion that the
longest TFS time is observed in patients with neither
ZAP-70 nor CD38 expression.
The results of the TFS analysis show the best prog-
nosis in patients with lack of ZAP-70 and CD38
expression, the group with the worst prognosis is the
one with ZAP-70+CD38+ phenotype. It seems that the
presence of positive CD38 expression on leukaemic
cells is the most important parameter determining the
shortening of TFS time.
The log-rank test showed significant difference in
the OS curves for groups ZAP-70-CD38- and ZAP-
70+CD38+, as well as for ZAP-70-CD38- and ZAP-
70-CD38+ (p=0.0001, p=0.0023). A significant differ-
ence in OS between groups ZAP-70-CD38- and ZAP-
70-CD38+ suggests that additional defining of CD38
expression enables to distinguish patients with better
and worse prognosis in ZAP-70- group (Fig. 3). Anal-
ysis of the data from Table 4 revealed that overall sur-
vival time was longer in ZAP-70-CD38- group in com-
parison with another three groups.
Additional information can be obtained by evaluat-
ing the survival curves in ZAP-70+CD38+ and ZAP-
70-CD38- groups depending on LDH activity, concen-
tration of β2M and hemoglobin. Because of lack of
decrease in favorable prognosis groups, only TFS but
not OS was defined. As for groups: ZAP+CD38+/LDH
>350U/l; ZAP+CD38+/β2M >3.0 mg/L and ZAP+
CD38+/Hb <12 g/dL the mean TFS was: 51.76; 48.9;
and 58.13 months and it was shorter in comparison
with ZAP+CD38+ patients (77.9 months).
Discussion
The aim of the presented study was to establish
whether combined analysis of ZAP-70 and CD38
expression could improve predictive impact of both
parameters. First, we confirmed their value as inde-
pendent prognostic factors using multivariate Cox
regression analysis. The importance of ZAP-70 as an
independent prognosis parameter has been shown in
numerous earlier studies [10,15,16], in the case of
CD38, this issue has been the matter of many contro-
versies. Hamblin et al. in a multifactoral analysis, con-
ducted in 2002, underlined that both IgVH mutational
status and CD38 expression were independent prog-
nostic factors [17], but according to Oscier et al. [18]
the expression of CD38 cannot play the role of an
independent prognostic parameter, but gives an addi-
tional predictive information in patients with defined
IgVH mutational status. Other research concerning the
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Table 3. Comparison of TFS in groups of patients with B-CLL with phenotype: ZAP-70-CD38-; ZAP-70-CD38+; ZAP-70+CD38-; ZAP-
70+CD38+.
Table 4. Comparison of OS in groups of patients with B-PBL with phenotype: ZAP-70-CD38-; ZAP-70-CD38+; ZAP-70+CD38-; ZAP-
70+CD38+.
value of CD38 as an independent prognosis parameter,
also revealed divergent results [8,15,16,19-22]. The
majority of recent studies conducted on large groups of
patients confirms the predictive significance of CD38
expression.  
For the clinical practice it is important to establish
whether combined evaluation of the two independent
prognostic factors, ZAP-70 and CD38 contribute to the
increase in their predictive value. According to
Orchard et al. CD38 expression has no influence on
the increase in the prognostic significance of ZAP-70
and IgVH mutational status [15]. Similar conclusions
were drawn by Del Principe et al. They stated that it
was adequate just to evaluate ZAP-70 expression [16].
However, the results of our studies are in favor of
simultaneous evaluation of both parameters that was
presented in the earlier publication concerning the dis-
cussed issue [12]. The analysis showed the concor-
dance in the results regarding the expression of the two
studied antigens in 72.7% of patients. In the group
with divergent results, 15.6% of patients were ZAP-
70+CD38- and 11.5% were characterized by the phe-
notype of ZAP-70-CD38+. In the studies of Del
Principe et al. the vast majority of patients from the
group with divergent expression of both factors was
characterized by the phenotype of ZAP-70+CD38-
(82%) which, according to the authors indicated a
major importance of ZAP-70 expression [16]. The
results of our studies do not confirm such observations
as the percentage of ZAP-70+CD38- and ZAP-70-
CD38+ patients was approximately the same. The
most significant differences in laboratory parameters
were found between ZAP-70-CD38- and ZAP-
70+CD38+ groups, whilst the differences between the
two groups with divergent expression of studied anti-
gens were not statistically significant. Corresponding
observations deal with the evaluation of survival
curves as well. Simultaneous evaluation of both anti-
gen expression enables to distinguish subgroups with
the best and the worst prognosis, which was revealed
in the earlier studies of other authors [10,11]. Schroers
et al, on the basis of combined evaluation of ZAP-70
and CD38 expression displayed three groups of
patients: the good prognosis group (event-free sur-
vival, EFS 130 months; phenotype ZAP-70-CD38-);
the poor prognosis group (EFS 30 months; phenotype
ZAP-70+CD38+) and the intermediate prognosis
group (EFS 43 months; phenotype ZAP-70+CD38+
and ZAP-70-CD38-) [10]. Similar data on the treat-
ment free survival were presented by Del Giaudice et
al, who also distinguished three groups with different
prognosis on the basis of ZAP-70 and CD38 evalua-
tion [11]. Furthermore, combined analysis used in our
study enabled to separate subgroups in ZAP-70+ as
well as in ZAP-70- patients, differing sometimes in OS
and TFS time. Analogically, evaluation of ZAP-70
expression helps to distinguish additional subgroups
among patients with positive or negative CD38
expression. These interdependences were acknowl-
edged as significant for the prognosis by Durig et al.
[4] and Bosch et al. [23]. The fact that the analysis of
survival curves presented in our studies revealed  that
shortening of TFS depends  more on CD38 expression,
but ZAP-70 expression has a major impact on shorten-
ing of OS is in favor of the importance of combined
evaluation of ZAP-70 and CD38 expression. Simulta-
neous evaluation of ZAP-70 and CD38 expression
approves to enroll patients into an appropriate prog-
nostic group in the case of threshold values of one of
the evaluated parameters. The results of our study
revealed also that analysis of ZAP-70 and CD38
expression together with chosen laboratory parameters
with prognostic importance (concentration of hemo-
globin and β2M, serum activity of LDH), enabled to
distinguish patients with a shorter TFS time than in
ZAP+CD38+ group. These observations may be of
great clinical value, since qualification of patients in
early stages of B-CLL for the therapy on the basis of
the presence of unfavourable prognostic parameters is
more often considered. Our results suggest that stan-
dardized evaluation of ZAP-70 and CD38 expression
ought to be included in the panel of routine laboratory
tests studies at B-CLL diagnosis. However, whilst tak-
ing therapeutic decisions, it would be advisable to
elaborate point system which would include both
ZAP-70 and CD38 expression, as well as other labora-
tory parameters with determined prognostic value. 
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